StarGen (SAR422459) / Oxford Biomedica 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   55 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
StarGen (SAR422459) / Oxford Biomedica
2012-001990-95: Phase I/II Follow-up Study of SAR422459 in Patients with Stargardt's Macular Degeneration

Not yet recruiting
1/2
27
Europe
SAR422459, Lentiviral vector containing the ABCA4 gene, Suspension for injection
sanofi-aventis recherche et développement, sanofi-aventis recherche et développement
Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease., Inherited juvenile macular degeneration, leading to deterioration ofcentral vision, and legally-defined blindness in young adults., Diseases [C] - Eye Diseases [C11]
 
 
NCT01736592: Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration

Calendar Jan 2034 - Dec 2034: Data in Stargardt’s macular degeneration
Active, not recruiting
1/2
27
Europe, US
Long term follow up in all patients who received SAR422459 in previous study TDU13583
Sanofi
Stargardt's Disease
08/33
08/33

Download Options